Alimera Sciences (ALIM) Misses Q2 EPS by 3c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. SWKS
7. ANET
8. SPY
9. XYZ
10. CVS

Go back to Alimera Sciences (ALIM) Misses Q2 EPS by 3c

Alimera Sciences Reports Second Quarter 2015 Financial Results

August 10, 2015 4:06 PM EDT

ATLANTA, Aug. 10, 2015 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced financial results for the second quarter ended June 30, 2015.

"The second quarter was our first full quarter of ILUVIEN® sales in the U.S., and we are very pleased with the results. In particular, ILUVIEN generated $3.8 million in sales in the U.S., which accounted for approximately 66% of our total revenue for the quarter with downstream demand from physicians increasing 180% from the first quarter of... More